Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company was founded by Peter Laurence Molloy and Stephen Goodall on April 12, 2012 and is headquartered in Melbourne, Australia.